# DEFB1

## Overview
The DEFB1 gene encodes the protein human beta-defensin 1 (hBD-1), a member of the defensin family of antimicrobial peptides. These peptides are integral to the innate immune system, providing a first line of defense against a broad spectrum of pathogens, including bacteria, fungi, and viruses. hBD-1 is characterized by its small, cationic, and cysteine-rich structure, which is essential for its antimicrobial activity. The protein is constitutively expressed in various epithelial tissues, such as the skin and respiratory tract, where it disrupts microbial membranes to inhibit pathogen proliferation. Beyond its antimicrobial properties, hBD-1 also plays a role in modulating inflammation and wound healing. Genetic variations in the DEFB1 gene can influence the expression and function of hBD-1, potentially affecting an individual's susceptibility to diseases like periodontitis, chronic obstructive pulmonary disease, and asthma (Cruz2020Regulatory; Kalus2009Association; Almutairi2021Human).

## Structure
The DEFB1 gene encodes the β-defensin 1 protein, a small cationic antimicrobial peptide involved in immune responses. The primary structure of β-defensin 1 consists of a sequence of amino acids that form the protein, characterized by a cysteine-rich composition. These cysteine residues are crucial for forming disulfide bonds, which stabilize the protein's tertiary structure (Taylor2008Structure–activity). The secondary structure of β-defensin 1 includes three β-strands arranged in an antiparallel sheet, flanked by an α-helical segment at the N-terminal fragment (Taylor2008Structure–activity).

The tertiary structure is maintained by three intramolecular disulfide bonds, with specific connectivity patterns: C I – C V, C II – C IV, and C III – C VI (Taylor2008Structure–activity). This structure is essential for the protein's antimicrobial activity, allowing it to bind to and permeabilize bacterial membranes (Venkata2020In). The β-defensin 1 protein does not have a quaternary structure as it functions as a single peptide unit.

Post-translational modifications, such as potential disulfide linkages, are crucial for the protein's stability and function (Venkata2020In). The DEFB1 gene is constitutively expressed by epithelial cells and interacts with immune cells via the CCR6 receptor, playing a role in antimicrobial and chemotactic activity (Venkata2020In).

## Function
The DEFB1 gene encodes human beta-defensin 1 (hBD-1), an antimicrobial peptide that plays a crucial role in the innate immune system. hBD-1 is constitutively expressed in various epithelial tissues, including the skin, respiratory tract, and oral cavity, where it acts as a first line of defense against a wide range of pathogens, including bacteria, fungi, and viruses (Kalus2009Association; Almutairi2021Human). The peptide functions by disrupting the membrane integrity of microorganisms, thereby inhibiting their proliferation and promoting their destruction (Loo2012Clinical).

hBD-1 is involved in maintaining the health of mucosal surfaces and contributes to the immune response by modulating inflammation and wound repair processes (Almutairi2021Human). Its expression can be upregulated in response to microbial or inflammatory stimuli, enhancing its protective effects (Cruz2020Regulatory). Genetic polymorphisms in the DEFB1 gene can influence the expression and function of hBD-1, potentially affecting susceptibility to various diseases, including periodontitis, chronic obstructive pulmonary disease, and asthma (Cruz2020Regulatory; Kalus2009Association). These polymorphisms may alter transcription factor binding sites, impacting the gene's regulatory mechanisms and its role in immune defense (Cruz2020Regulatory).

## Clinical Significance
Mutations and alterations in the DEFB1 gene have been associated with various diseases and conditions. The SNP 668C in the DEFB1 gene is linked to lepromatous leprosy, a severe form of leprosy. This SNP alters a putative NF-κB1 binding site, potentially affecting the gene's expression and contributing to disease susceptibility (PradoMontes2009SNP). The presence of the 668C variant is associated with a more severe form of leprosy, possibly due to altered NF-kB-dependent upregulation of DEFB1 (PradoMontes2009SNP).

In chronic respiratory diseases (CRDs), polymorphisms in DEFB1, such as -44 C/G and 1654 G/A, have been linked to increased susceptibility to conditions like chronic obstructive pulmonary disease (COPD), ventilator-associated pneumonia (VAP), and cystic fibrosis (Ran2016Betadefensin). These polymorphisms may influence the expression of DEFB1, affecting the innate immune response and increasing disease risk.

The DEFB1 gene is also implicated in susceptibility to invasive mold infections in solid-organ transplant recipients. A polymorphism, rs1800972, is associated with an increased risk of mold colonization and infection, highlighting the gene's role in modulating immune responses (Wojtowicz2014IL1B).

## Interactions
DEFB1, encoding the human β-defensin 1 protein, participates in several interactions crucial for its role in the immune response. One significant interaction is with the chemokine receptor CCR6, which is expressed by immune cells such as dendritic cells and memory T cells. This interaction facilitates the recruitment of these immune cells to sites of microbial invasion, enhancing the immune response (Venkata2020In). 

The DEFB1 gene is also involved in regulatory interactions through its promoter region. The regulatory SNP rs5743417 in the DEFB1 gene affects transcription factor binding sites, including those for CREB1, SREBF2, and JUND. These interactions are important for the regulation of DEFB1 expression and can influence susceptibility to diseases like COPD and asthma (Cruz2020Regulatory). 

Additionally, DEFB1 is implicated in the modulation of immune responses through its chemotactic effects and potential role as a tumor suppressor gene. It is suggested to induce cancer cell apoptosis, which may be linked to its interactions with other immune system components (Rabjerg2016Molecular). These interactions highlight the multifaceted role of DEFB1 in both antimicrobial activity and immune regulation.


## References


[1. (Almutairi2021Human) Mikhlid Almutairi, Bader Almutairi, Mohammad Almutairi, Narasimha Reddy Parine, Abdulwahed Alrefaei, Mohammad Alanazi, and Abdelhabib Semlali. Human beta-defensin-1 rs2738047 polymorphism is associated with shisha smoking risk among saudi population. Environmental Science and Pollution Research, 28(31):42916–42933, April 2021. URL: http://dx.doi.org/10.1007/s11356-021-13660-9, doi:10.1007/s11356-021-13660-9. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s11356-021-13660-9)

[2. (PradoMontes2009SNP) Ernesto Prado-Montes de Oca, Jesús Salvador Velarde-Félix, Juan José Ríos-Tostado, Verónica Judith Picos-Cárdenas, and Luis Eduardo Figuera. Snp 668c (−44) alters a nf-κb1 putative binding site in non-coding strand of human β-defensin 1 (defb1) and is associated with lepromatous leprosy. Infection, Genetics and Evolution, 9(4):617–625, July 2009. URL: http://dx.doi.org/10.1016/j.meegid.2009.03.006, doi:10.1016/j.meegid.2009.03.006. This article has 41 citations.](https://doi.org/10.1016/j.meegid.2009.03.006)

[3. (Venkata2020In) Harini Venkata Subbiah, Polani Ramesh Babu, and Usha Subbiah. In silico analysis of non-synonymous single nucleotide polymorphisms of human defb1 gene. Egyptian Journal of Medical Human Genetics, November 2020. URL: http://dx.doi.org/10.1186/s43042-020-00110-3, doi:10.1186/s43042-020-00110-3. This article has 15 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s43042-020-00110-3)

[4. (Wojtowicz2014IL1B) A. Wojtowicz, M. S. Gresnigt, T. Lecompte, S. Bibert, O. Manuel, L. A. B. Joosten, S. Rueger, C. Berger, K. Boggian, A. Cusini, C. Garzoni, H. H. Hirsch, M. Weisser, N. J. Mueller, P. R. Meylan, J. Steiger, Z. Kutalik, M. Pascual, C. van Delden, F. L. van de Veerdonk, P.-Y. Bochud, the Swiss Transplant Cohort Study (STCS), I. Binet, S. De Geest, C. van Delden, G. F. K. Hofbauer, U. Huynh-Do, M. T. Koller, C. Lovis, O. Manuel, P. Meylan, N. J. Mueller, M. Pascual, S. Schaub, and J. Steiger. Il1b and defb1 polymorphisms increase susceptibility to invasive mold infection after solid-organ transplantation. Journal of Infectious Diseases, 211(10):1646–1657, November 2014. URL: http://dx.doi.org/10.1093/infdis/jiu636, doi:10.1093/infdis/jiu636. This article has 52 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/infdis/jiu636)

[5. (Kalus2009Association) Andrea A Kalus, L Page Fredericks, Beth M Hacker, Henrik Dommisch, Richard B Presland, Janet R Kimball, and Beverly A Dale. Association of a genetic polymorphism (-44 c/g snp) in the human defb1 gene with expression and inducibility of multiple β-defensins in gingival keratinocytes. BMC Oral Health, August 2009. URL: http://dx.doi.org/10.1186/1472-6831-9-21, doi:10.1186/1472-6831-9-21. This article has 42 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1472-6831-9-21)

[6. (Loo2012Clinical) Wings TY Loo, Lan-jun Bai, Chang-bin Fan, Yuan Yue, Yi-ding Dou, Min Wang, Hao Liang, Mary NB Cheung, Louis WC Chow, Jin-le Li, Ye Tian, and Liu Qing. Clinical application of human β-defensin and cd14 gene polymorphism in evaluating the status of chronic inflammation. Journal of Translational Medicine, September 2012. URL: http://dx.doi.org/10.1186/1479-5876-10-S1-S9, doi:10.1186/1479-5876-10-s1-s9. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1479-5876-10-S1-S9)

[7. (Cruz2020Regulatory) Luis Antonio Cruz Díaz, Abel Gutiérrez Ortega, Rocío del Carmen Chávez Álvarez, Jesús Salvador Velarde Félix, and Ernesto Prado Montes de Oca. Regulatory snp rs5743417 impairs constitutive expression of human β‐defensin 1 and has high frequency in africans and afro‐americans. International Journal of Immunogenetics, 47(4):332–341, January 2020. URL: http://dx.doi.org/10.1111/iji.12475, doi:10.1111/iji.12475. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/iji.12475)

[8. (Rabjerg2016Molecular) Maj Rabjerg, Henriette Bjerregaard, Ulrich Halekoh, Boye L. Jensen, Steen Walter, and Niels Marcussen. Molecular characterization of clear cell renal cell carcinoma identifies <scp>csnk</scp>2a1, <scp>spp</scp>1 and <scp>defb</scp>1 as promising novel prognostic markers. APMIS, 124(5):372–383, February 2016. URL: http://dx.doi.org/10.1111/apm.12519, doi:10.1111/apm.12519. This article has 33 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/apm.12519)

[9. (Taylor2008Structure–activity) Karen Taylor, Perdita E. Barran, and Julia R. Dorin. Structure–activity relationships in β‐defensin peptides. Peptide Science, 90(1):1–7, January 2008. URL: http://dx.doi.org/10.1002/bip.20900, doi:10.1002/bip.20900. This article has 109 citations.](https://doi.org/10.1002/bip.20900)

[10. (Ran2016Betadefensin) Xiaodan Ran, Jinghui Chen, Lu Chen, Yongwei Li, and Mengzhi Wu. Beta-defensin gene (defb1) polymorphisms are associated with the susceptibility to chronic respiratory diseases. Genes &amp; Genomics, 38(7):645–658, February 2016. URL: http://dx.doi.org/10.1007/s13258-016-0388-4, doi:10.1007/s13258-016-0388-4. This article has 3 citations.](https://doi.org/10.1007/s13258-016-0388-4)